Literature DB >> 28379326

An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia.

Eric Wenzler1, Fei Wang2, Debra A Goff2, Beth Prier2, John Mellett2, Julie E Mangino3, Karri A Bauer2.   

Abstract

BACKGROUND: Infectious diseases (ID) consultation and antimicrobial stewardship intervention have been shown to improve the management of Staphylococcus aureus bacteremia (SAB). As the workload of antimicrobial stewardship programs (ASPs) continues to increase, ASPs must find a way to maximize the efficiency of the program while optimizing patient outcomes. The objective of this study was to evaluate the impact of incorporating health informatics into the management of SAB via a pharmacist-driven initiative.
METHODS: Retrospective, single-center quasi-experimental study of hospitalized patients with SAB. During the intervention period, pharmacists were alerted to patients with SAB via a patient scoring tool integrated into the electronic medical record. Pharmacists utilized the scoring tool and the institution's evidence-based practice guideline to make standardized recommendations to promote adherence to SAB quality-of-care measures and encourage ID consultation. The primary outcome was overall compliance along with adherence to individual quality-of-care components. Secondary clinical outcomes were also analyzed.
RESULTS: In sum, 84 patients were identified for study inclusion, 45 in the pre-intervention and 39 in the intervention group. As a whole, all 4 quality-of-care components for the management of SAB were significantly more frequently adhered to in the intervention group (68.9% vs 92.3%; P = .008). The incidence of ID consult improved significantly by almost 20% in the intervention group (75.6% vs 94.9%, P = .015). No statistically significant differences in duration of bacteremia, length-of-stay, infection-related length-of-stay, or readmission were observed between the groups. The incidence of all-cause mortality was 6-fold higher in the pre- intervention group compared to the intervention group (15.6% vs 2.6%, P = .063).
CONCLUSION: An automated, pharmacist-driven intervention for the management of patients with SAB demonstrated a significant improvement in patients receiving an ID consult, targeted antimicrobial therapy, and adherence to all SAB quality-of-care measures. As antimicrobial stewardship becomes a mandatory aspect of healthcare in all hospitals in the United States, ASPs will be forced to find ways to provide more efficient, impactful, disease state-based patient care. Our study provides the framework for and data to support this intervention in one of the most clinically important infectious diseases.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Staphylococcus aureus; bacteremia; pharmacist; process measure; quality of care

Mesh:

Substances:

Year:  2017        PMID: 28379326     DOI: 10.1093/cid/cix315

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Role of pharmacists in antimicrobial stewardship programmes.

Authors:  Javier Garau; Matteo Bassetti
Journal:  Int J Clin Pharm       Date:  2018-09-22

2.  Antibiotic Stewardship: The Health of the World Depends on It.

Authors:  Debra A Goff
Journal:  Hosp Pharm       Date:  2018-04-19

Review 3.  Common Models Used for Inpatient Diabetes Management.

Authors:  Andjela T Drincic; Padmaja Akkireddy; Jon T Knezevich
Journal:  Curr Diab Rep       Date:  2018-02-14       Impact factor: 4.810

4.  Duration of Antibiotic Therapy for General Medicine and General Surgery Patients Throughout Transitions of Care: An Antibiotic Stewardship Opportunity for Noninfectious Disease Pharmacists.

Authors:  Kristin I Brower; Ariel Hecke; Julie E Mangino; Anthony T Gerlach; Debra A Goff
Journal:  Hosp Pharm       Date:  2020-06-15

5.  A Pharmacist-Driven Glycemic Control Protocol to Reduce the Rate of Severe Hypoglycemia in High-Risk Patients.

Authors:  Colleen A Cook; Victor Vakayil; Kyle Pribyl; Derek Yerxa; John Kriz; Angie Case; Steven Meisel; Tammy Ho; James V Harmon
Journal:  Hosp Pharm       Date:  2020-11-24

6.  Impact of an Unsolicited, Standardized Form-Based Antimicrobial Stewardship Intervention to Improve Guideline Adherence in the Management of Staphylococcus aureus Bacteremia.

Authors:  Shahileen Remtulla; Karen Zurek; Carlos Cervera; Cristina Hernandez; Mao-Cheng Lee; Holly L Hoang
Journal:  Open Forum Infect Dis       Date:  2019-02-26       Impact factor: 3.835

7.  Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia.

Authors:  Reaghan M Erickson; Brandon J Tritle; Emily S Spivak; Tristan T Timbrook
Journal:  Open Forum Infect Dis       Date:  2019-11-13       Impact factor: 3.835

8.  Impact of Mandatory Infectious Diseases Consultation and Real-time Antimicrobial Stewardship Pharmacist Intervention on Staphylococcus aureus Bacteremia Bundle Adherence.

Authors:  Kellie Arensman; Jennifer Dela-Pena; Jessica L Miller; Erik LaChance; Maya Beganovic; Morgan Anderson; Anne Rivelli; Sarah M Wieczorkiewicz
Journal:  Open Forum Infect Dis       Date:  2020-05-21       Impact factor: 3.835

9.  Antimicrobial Stewardship Review of Automated Candidemia Alerts Using the Epic Stewardship Module Improves Bundle-of-Care Adherence.

Authors:  Natasha N Pettit; Zhe Han; Cynthia T Nguyen; Anish Choksi; Angella Charnot-Katsikas; Kathleen G Beavis; Vera Tesic; Jennifer Pisano
Journal:  Open Forum Infect Dis       Date:  2019-10-11       Impact factor: 3.835

10.  Successful Use of Telemedicine Infectious Diseases Consultation With an Antimicrobial Stewardship-Led Staphylococcus aureus Bacteremia Care Bundle.

Authors:  Jacqueline Meredith; Jennifer Onsrud; Lisa Davidson; Leigh Ann Medaris; Marc Kowalkowski; Kristin Fischer; Jennifer Priem; Michael Leonard; Lewis McCurdy
Journal:  Open Forum Infect Dis       Date:  2021-05-10       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.